Connor Clark & Lunn Investment Management Ltd. trimmed its stake in Ovid Therapeutics Inc. (NASDAQ:OVID – Free Report) by 22.7% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 30,858 shares of the company’s stock after selling 9,062 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Ovid Therapeutics were worth $80,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in the stock. Madison Avenue Partners LP increased its stake in Ovid Therapeutics by 95.2% in the fourth quarter. Madison Avenue Partners LP now owns 2,721,051 shares of the company’s stock valued at $5,061,000 after purchasing an additional 1,327,029 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Ovid Therapeutics by 7.1% during the 1st quarter. Vanguard Group Inc. now owns 3,687,909 shares of the company’s stock valued at $11,580,000 after buying an additional 245,291 shares during the period. Tejara Capital Ltd purchased a new stake in shares of Ovid Therapeutics during the 4th quarter valued at $200,000. Jane Street Group LLC acquired a new stake in shares of Ovid Therapeutics during the 1st quarter worth $199,000. Finally, State Street Corp boosted its holdings in Ovid Therapeutics by 32.4% in the first quarter. State Street Corp now owns 191,733 shares of the company’s stock valued at $602,000 after acquiring an additional 46,884 shares during the last quarter. 56.64% of the stock is owned by institutional investors and hedge funds.
Ovid Therapeutics Price Performance
OVID stock opened at $3.79 on Wednesday. The stock has a 50-day moving average price of $3.54 and a two-hundred day moving average price of $3.20. The company has a market cap of $267.57 million, a PE ratio of -5.41 and a beta of 1.08. The company has a current ratio of 10.07, a quick ratio of 10.07 and a debt-to-equity ratio of 0.14. Ovid Therapeutics Inc. has a 12-month low of $1.40 and a 12-month high of $4.14.
About Ovid Therapeutics
Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.
- Five stocks we like better than Ovid Therapeutics
- 5 Top Rated Dividend Stocks to Consider
- 3 Inexpensive Mid Cap Tech Stocks With Good Growth Prospects
- How to Invest in Grocery Stores
- 3 Reasons the Dick’s Sporting Goods Selloff Is a Steal
- Dividend Payout Ratio Calculator
- Foot Locker Stock Takes a Big Hit…Is It a Retail Bargain?
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.